Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,084 across all filing types
Latest filing 2024-04-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the release of a portion of pledged shares by a controlling shareholder. It details the number of shares released from pledge, the shareholder's pledge status, and related information. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share pledge status, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like share issue or director dealings.
2024-04-29 Chinese
独立董事专门会议制度
Governance Information Classification · 95% confidence The document is titled '独立董事专门会议制度' which translates to 'Independent Directors Special Meeting System'. It outlines the rules, procedures, and governance mechanisms for independent directors' meetings within the company. The content focuses on governance practices, meeting protocols, voting rights, and responsibilities of independent directors. There is no financial data, no mention of financial results, no regulatory filings, no announcements of votes or dividends, and no references to annual or interim reports. The document is a governance-related internal policy document. Therefore, it fits best under Governance Information (CGR). The document length is 2425 characters, which is relatively short but contains substantive governance content rather than being a mere announcement or certification.
2024-04-25 Chinese
防范控股股东、实际控制人及关联方占用公司资金专项制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '防范大股东及关联方占用公司资金专项制度' (Special System for Preventing Major Shareholders and Related Parties from Occupying Company Funds) issued by 西藏易明西雅医药科技股份有限公司. It outlines rules, responsibilities, and procedures to prevent misuse of company funds by controlling shareholders and related parties. There is no indication that this is a financial report, audit report, or regulatory filing. It is a governance-related document focusing on internal controls and corporate governance practices regarding fund management and prevention of related-party fund occupation. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Legal Proceedings. The content aligns best with Governance Information (CGR), which covers internal rules and governance practices of the company.
2024-04-25 Chinese
2023年度独立董事述职报告-冯岚
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It details the independent director's background, attendance at board and shareholder meetings, committee participation, communication with auditors, and oversight activities during the year 2023. It includes evaluations of company governance, compliance with laws, and shareholder interests. The document is a detailed report on the independent director's duties and activities over the year, not an announcement or a brief summary. It is not a full annual report (10-K) or audit report but a management-related report focusing on board and director activities. This fits best under Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management. The document is substantive and specific to the independent director's role and performance for the year 2023.
2024-04-25 Chinese
中小投资者单独计票管理办法
Governance Information Classification · 95% confidence The document is titled '中小投资者单独计票管理办法' which translates to 'Management Measures for Separate Voting of Small and Medium Investors'. It outlines procedures and rules for voting by small and medium investors in shareholder meetings, including definitions, voting procedures, disclosure requirements, and legal compliance. The content is regulatory and procedural in nature, focusing on governance and shareholder voting rights rather than financial results, audit opinions, or management changes. It does not contain financial statements or earnings data, nor is it an announcement of a report. It is not a proxy solicitation or voting results announcement but rather a governance-related policy document. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2470 characters, which is relatively short but contains substantive governance rules rather than a mere announcement or certification.
2024-04-25 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度内部控制自我评价报告' which translates to '2023 Annual Internal Control Self-Evaluation Report'. It is a detailed report on the company's internal control evaluation for the year ending December 31, 2023. The content includes internal control scope, evaluation conclusions, control activities, risk assessments, and defect identification standards. It is a comprehensive internal control report, not an announcement or a brief summary. It does not fit categories like Annual Report (10-K) or Audit Report (AR) but is clearly an internal control self-evaluation report, which aligns with the Audit Report / Information (AR) category as it relates to audit and internal control results. The document length is over 10,000 characters, indicating it is a full report, not a publication announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2023
2024-04-25 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.